Livforsakringsbolaget Skandia, Omsesidigt Vertex Pharmaceuticals Inc Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.85 Billion
- Q4 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 27,820 shares of VRTX stock, worth $13.5 Million. This represents 0.6% of its overall portfolio holdings.
Number of Shares
27,820
Previous 2,180
1176.15%
Holding current value
$13.5 Million
Previous $1.01 Million
1005.92%
% of portfolio
0.6%
Previous 0.06%
Shares
24 transactions
Others Institutions Holding VRTX
# of Institutions
1,764Shares Held
222MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.7 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$11.3 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.3 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.81 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$5.06 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $124B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...